Skip to main content
. 2016 Jun 30;5(7):e1192740. doi: 10.1080/2162402X.2016.1192740

Figure 3.

Figure 3.

Treatment with αCD20 and αCD137 induces BAFF and cytokines in plasma with or without B lymphoma inoculation. Control Ig (2A3, 250 μg i.p.) or anti-CD20 (clone 5D2, 250 μg i.p.) was administered on day (D) 0, and anti-CD137 (clone 3H3, 100 μg i.p.) either alone or in combination on D1 in C57BL6 wild-type (WT) or gene-targeted mice. In some experiments (B, D), 1 × 105 BL3750 cells were injected intravenously on day (D) 0, and control Ig (2A3, 250 μg i.p.) or anti-CD20 (clone 5D2, 250 μg i.p.) was administered on day (D) 4, and anti-CD137 (clone 3H3, 100 μg i.p.) either alone or in combination on D5 in WT or gene-targeted mice. (A) and (B) BAFF assessment from plasma of mice at D2, D5, D8 and D15 post anti-CD20 treatment. Data is representative of two experiment, n = 5 each group (n = 10 total).